Parkinson’s Disease Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By Region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

4.80 billion

CAGR (2023-2028)

7.50%

Fastest Growing Segment

Hospital Pharmacies

Largest Market

North America

 

Market Overview

Global Parkinson’s Disease Drugs Market has valued at USD 4.80 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2028. Parkinson's disease is a chronic and progressive neurodegenerative disorder of the central nervous system that primarily affects movement control. It is characterized by a range of motor symptoms and can also involve non-motor symptoms. Resting tremors are a hallmark symptom of Parkinson's disease. These involuntary shaking movements typically occur when the affected limb is at rest and often involve a rhythmic "pill-rolling" motion of the fingers. Muscle stiffness and increased resistance to passive movement are common in Parkinson's disease. This rigidity can affect various muscle groups and lead to a sense of physical discomfort. Balance problems and a tendency to fall can develop as Parkinson's disease progresses. Individuals may have difficulty maintaining an upright posture and may experience unexplained falls. Parkinson's disease can involve a range of non-motor symptoms, including mood changes (such as depression and anxiety), sleep disturbances, cognitive impairment, autonomic dysfunction (such as constipation and orthostatic hypotension), and sensory changes.

Parkinson's disease is becoming more common, with a growing number of diagnosed cases globally. This trend increases the need for effective pharmaceutical treatments. Pharmaceutical companies are investing in research and development to create more effective and innovative drugs for Parkinson's disease. This includes developing drugs that not only alleviate symptoms but also potentially slow the progression of the disease. Greater awareness of Parkinson's disease among healthcare professionals and the public has led to earlier diagnosis and treatment. This drives the demand for drugs to manage the condition. Beyond traditional treatments, there is growing interest in emerging therapies, such as gene therapies, stem cell therapies, and neuroprotective agents. These therapies offer the potential for disease modification, further driving the market.

Key Market Drivers

Advancements in Technology

Implantable or wearable devices that deliver medication continuously or on-demand have been developed. These devices can provide a more stable and consistent drug delivery, reducing motor fluctuations and the need for frequent dosing. Advances in drug formulation techniques have led to the development of extended-release and controlled-release formulations. These formulations can help maintain therapeutic drug levels in the body over an extended period, reducing the frequency of medication administration. Inhalable levodopa formulations have been developed to provide rapid relief of motor symptoms. These inhalers can be particularly beneficial for patients who experience sudden "off" periods. Research is ongoing to identify and develop neuroprotective drugs that may slow the progression of Parkinson's disease. These drugs aim to protect and preserve dopamine-producing neurons in the brain. Advances in genetic testing and biomarker identification are enabling more personalized treatment approaches. Tailoring medication regimens to an individual's genetic profile and disease stage can optimize treatment outcomes. Prodrugs are inactive compounds that convert into active drugs within the body. Some prodrugs have been designed to improve the delivery of levodopa, the primary treatment for PD, and reduce side effects.

Non-invasive focused ultrasound is being explored as a potential treatment for PD. This technology can be used to target and disrupt brain regions responsible for tremors and other motor symptoms. Deep Brain Stimulation (DBS) is a surgical procedure that involves implanting electrodes in the brain to modulate neural activity. Ongoing technological improvements in electrode design and stimulation techniques aim to enhance the effectiveness of DBS as a treatment option. The integration of telemedicine and remote monitoring technologies allows healthcare providers to monitor patients' symptoms and adjust medication regimens remotely, improving patient care and reducing the need for frequent in-person visits. Artificial intelligence and machine learning algorithms are being employed to analyze data from wearable devices and sensors to track disease progression and predict "off" periods, enabling more proactive medication adjustments. Virtual Reality (VR) -based rehabilitation programs are being developed to improve motor function and balance in PD patients. These technologies provide interactive and engaging exercises. This factor will help in the development of Global Parkinson’s Disease Drugs Market.

Rising Disease Prevalence

Parkinson's disease primarily affects older individuals. As the global population ages, there is a natural increase in the number of people at risk for developing Parkinson's disease. This demographic shift is a major driver of the rising prevalence. Advances in healthcare and improved living conditions have increased life expectancy worldwide. With people living longer, the risk of developing age-related neurodegenerative diseases like Parkinson's increases. Greater awareness of Parkinson's disease among healthcare professionals and the public has led to earlier and more accurate diagnoses. Improved diagnostic criteria and access to healthcare services have contributed to a higher number of reported cases. The overall growth of the world's population also plays a role. A larger population means a larger pool of individuals at risk for Parkinson's disease. Some studies suggest that environmental factors, such as exposure to pesticides and industrial chemicals, may contribute to the risk of developing Parkinson's disease. Changes in environmental conditions and increased urbanization could impact disease prevalence.

While Parkinson's disease is not purely genetic, certain genetic mutations and family history can increase the risk of developing the disease. As genetic testing becomes more accessible, more individuals at risk may be identified. Public health campaigns and educational initiatives have encouraged more people to seek medical attention for early signs of Parkinson's disease. Screening programs and outreach efforts can lead to earlier detection. Changes in lifestyle and dietary habits, including factors like obesity and exposure to certain toxins, can influence the risk of developing Parkinson's disease. These trends can vary by region and contribute to differences in disease prevalence. Improvements in healthcare infrastructure and access to medical services, especially in developing regions, mean that more people can receive a Parkinson's diagnosis and treatment. Parkinson's disease research and advocacy organizations have worked to raise awareness about the condition and push for increased funding and resources for research, which has led to improved understanding and diagnosis of the disease. This factor will pace up the demand of Global Parkinson’s Disease Drugs Market.

Emerging Therapies

Emerging therapies in Parkinson's disease are innovative approaches that aim to provide more effective treatment options, potentially slow disease progression, and improve the overall quality of life for individuals living with this neurodegenerative condition. Gene therapy involves altering or replacing faulty genes to treat or prevent disease. In Parkinson's disease, researchers are exploring gene therapy approaches to enhance the production of dopamine or protect dopamine-producing neurons. Promising targets include the GDNF (glial cell-derived neurotrophic factor) gene. Stem cell therapies aim to replace damaged or lost dopamine-producing neurons in the brain. Researchers are investigating the use of various stem cell types, including induced pluripotent stem cells (iPSCs) and embryonic stem cells, to generate dopamine neurons for transplantation. Several drugs and compounds are under investigation for their potential to protect and preserve dopamine-producing neurons in the brain. These agents may have disease-modifying effects and slow the progression of Parkinson's disease. Alpha-synuclein is a protein that forms abnormal aggregates in the brains of individuals with Parkinson's disease. Therapies aimed at reducing alpha-synuclein aggregation or clearing existing aggregates are being explored as potential disease-modifying treatments. Inflammation in the brain is thought to play a role in the progression of Parkinson's disease. Immunotherapies and anti-inflammatory drugs are being investigated to determine if they can slow disease progression or reduce symptoms. Non-invasive focused ultrasound is being studied as a potential treatment for Parkinson's disease. It can be used to target and disrupt brain regions responsible for tremors and other motor symptoms.

Optogenetics is a cutting-edge technique that involves using light-sensitive proteins to control the activity of specific neurons in the brain. Researchers are exploring optogenetic approaches to modulate neural circuits involved in Parkinson's symptoms. Tau protein abnormalities have been associated with Parkinson's disease. Emerging therapies targeting tau protein aggregates are being investigated as potential disease-modifying treatments. Advances in biomarker research may lead to the development of therapies tailored to specific subtypes of Parkinson's disease. These therapies aim to target the underlying molecular mechanisms of the disease. Neurofeedback and Brain-Computer Interfaces (BCIs) are being explored to assist patients in regaining control over their movements and alleviate Parkinson's symptoms. These technologies provide real-time feedback and assist in motor rehabilitation. Tailoring treatment regimens to an individual's genetic profile and disease stage is a growing focus in Parkinson's disease management. Precision medicine approaches aim to optimize therapy for each patient's specific needs. Nanotechnology may offer novel drug delivery methods, such as nanoparticles that can target specific brain regions or deliver therapeutic agents more effectively to the brain. This factor will accelerate the demand of Global Parkinson’s Disease Drugs Market.


Download Free Sample Report

Key Market Challenges

Side Effects and Tolerability

Some Parkinson's disease drugs, particularly levodopa, can lead to motor fluctuations, including "on-off" periods, dyskinesias (involuntary movements), and wearing-off phenomena. These fluctuations can be disruptive and challenging to manage. Many Parkinson's drugs can cause gastrointestinal side effects such as nausea, vomiting, and constipation. These side effects can affect medication absorption and patient compliance. Dopaminergic medications, including dopamine agonists, can lead to psychiatric side effects like hallucinations, impulse control disorders, and mood disturbances. These can have a significant impact on a patient's mental well-being. Some medications may exacerbate cognitive impairment in Parkinson's disease patients, particularly in advanced stages of the disease. This can include impairments in memory, attention, and executive function. Parkinson's disease drugs can lower blood pressure, leading to orthostatic hypotension, a condition where blood pressure drops significantly upon standing. This can result in dizziness, falls, and fainting. Medications can affect sleep patterns, leading to insomnia or excessive daytime sleepiness. Sleep disturbances can further worsen the quality of life for patients. Dopamine agonists can sometimes cause impulsive behaviors, including gambling and hypersexuality. These behaviors can strain relationships and have financial and social consequences. Patients with Parkinson's disease often take multiple medications to manage their symptoms and comorbid conditions. Drug interactions can occur, potentially leading to adverse effects or reduced drug efficacy.

Limited Efficacy of Current Treatments

Over time, many patients with Parkinson's disease experience motor fluctuations, characterized by periods of "on" (when medication is working well) and "off" (when medication is less effective). These fluctuations can lead to unpredictable symptom changes and reduced quality of life. Levodopa, a common dopaminergic medication used in Parkinson's disease treatment, can lose its effectiveness over time. Patients may require higher doses, leading to increased risk of side effects. Parkinson's disease is associated with a range of non-motor symptoms, including cognitive impairment, depression, anxiety, sleep disturbances, and autonomic dysfunction. Current treatments often provide limited relief for these non-motor symptoms. While existing drugs can manage symptoms, they do not address the underlying neurodegenerative process that causes Parkinson's disease. As the disease progresses, patients may become less responsive to medication, and symptoms may worsen. Some patients develop tolerance to dopaminergic medications, leading to reduced effectiveness. Moreover, long-term use of these drugs can result in dyskinesias (involuntary movements) that are challenging to manage. Current treatments may not adequately address cognitive impairment, which can be a significant challenge for patients and caregivers.

Key Market Trends

Patient-Centric Approaches

Recognizing that Parkinson's disease can manifest differently in each patient, healthcare providers are increasingly tailoring treatment plans to the specific needs and characteristics of individuals. Genetic testing and other biomarker assessments may be used to determine the most appropriate medications and dosages. Patient-centric care emphasizes the importance of involving patients in their own care decisions. It considers their preferences, values, and goals when developing treatment plans. This approach fosters a collaborative relationship between patients and healthcare providers. Shared decision-making is a fundamental aspect of patient-centric care. It involves a two-way exchange of information and decision-making between patients and healthcare providers to determine the most suitable treatment options based on the patient's preferences and circumstances. Educating patients about their condition, treatment options, and self-management strategies is crucial. Empowering patients with knowledge enable them to actively participate in their care and make informed decisions. A patient-centric approach often involves a multidisciplinary care team, including neurologists, physical therapists, occupational therapists, speech therapists, and mental health professionals. This team collaborates to address the diverse needs of Parkinson's patients.

Segmental Insights

Mechanism of Action Insights

In 2022, the Global Parkinson’s Disease Drugs Market largest share was dominated by MAO-B inhibitors segment in the forecast period and is predicted to continue expanding over the coming years. Dopamine and other chemicals in the brain are broken down by the Monoamine Oxidase Type B (MAO-B) enzyme in the human body. An MAO-B inhibitor, a medication, increases the amount of dopamine available for the brain to use, which can mildly alleviate several of Parkinson's Disease (PD) movement symptoms. To treat PD, MOA-B inhibitors have lately become popular. Over the projection period, this is anticipated to accelerate segment growth. Monoamine oxidase-B (MAO-B) inhibitors are commonly used to treat Parkinson's disease symptoms, according to the paper "Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future" published in February 2022.Parkinson's disease can be effectively treated in its early stages with MAO-B inhibitor monotherapy and in its later stages with MAO-B inhibitors used as adjuvant therapy. Growth in the segment is therefore anticipated because of research and development.

Distribution Channel Insights

In 2022, the Global Parkinson’s Disease Drugs Market largest share was dominated by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Hospital pharmacies are often associated with healthcare institutions, including hospitals and specialized neurological clinics. Parkinson's disease is a complex neurological disorder, and individuals with Parkinson's often receive specialized care and treatment in hospital settings. This makes hospital pharmacies a primary source for obtaining prescription medications specific to Parkinson's disease. Most medications used to manage Parkinson's disease symptoms are prescription drugs. Hospital pharmacies play a critical role in dispensing these prescription medications to patients. Neurologists and movement disorder specialists, who typically treat Parkinson's disease patients, often work within hospital settings, further increasing the utilization of hospital pharmacies. Hospitals are often at the forefront of Parkinson's disease research and clinical trials. As a result, they may dispense experimental medications and participate in drug development programs, which can contribute to a significant portion of the Parkinson's drug market.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Parkinson’s Disease Drugs Market in 2022. The United States currently controls a sizeable portion of the market in North America, and it is anticipated that it will continue to rule during the projection period. The high cost of healthcare, the dominance of large market players, the regular approval of new products, and the rise in Parkinson's disease patients can all be considered contributing causes.  Additionally, the FDA in the United States and other nations in the region has frequently approved products due to the rising number of cases of the condition in the nation. For instance, Parkinson's Disease (PD), the neurological condition with the greatest rate of growth in the United States and one of the conditions for which there is currently no cure, is treated with DHIVY, which was given FDA approval in November 2021. Over the course of the analysis period, the FDA's approvals are anticipated to support market expansion.

Recent Developments

  • In August 2023, The FDA has approved Aspen Neuroscience's application for an Investigational New Drug (IND) for a new Parkinson's Disease gene treatment, the company reported. The company is now free to start clinical trials thanks to this clearance. The medication aims to restore damaged neuronal cells in Parkinson's disease sufferers. The three parts of the therapy process are described in the news release. A small sample of the patient's stem cells is first taken by the medical staff.
  • In May 2022, For the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD), AbbVie has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa). The goal of ABBV-951 is to offer a unique, continuous, 24-hour subcutaneous delivery of CD/LD. It provides the potential for improvement in motor fluctuations in patients with advanced Parkinson's disease, a chronic, progressive neurological disorder caused by the loss of dopamine-producing brain cells.1 Parkinson's disease is primarily characterized by tremor, muscle rigidity, sluggish movement, and balance issues. In Parkinson's disease (PD), patients and their healthcare professionals have the same objective: to increase the amount of "On" time, which refers to the time when symptoms are well-controlled and free of dyskinesia or uncontrollable movements.
  • In January 2022, to develop and commercialise ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier (BBB) penetration, ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced an exclusive collaboration and worldwide licence agreement with SANOFI. The worldwide exclusive rights to develop and market ABL301 will go to SANOFI. ABL301's preclinical development and Phase 1 clinical trial will be overseen by ABL. The subsequent clinical development, regulatory approval, and global commercialization of ABL301 will be handled by SANOFI. An anti-alpha-synuclein antibody and Grabody-B, a BBB-penetrating shuttle that targets the insulin-like growth factor 1 receptor (IGF1R), are combined to form the bispecific antibody known as ABL301. For the treatment of synucleinopathies, such as Parkinson's disease, it is being developed as a potential first-in-class bispecific antibody therapy.

Key Market Players

  • Amneal Pharmaceuticals LLC
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • GSK plc
  • Teva Pharmaceuticals Industries Ltd
  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Kissei Pharmaceutical Co., Ltd.
  • AstraZeneca Plc
  • Prevail Therapeutics Inc.
  • Newron Pharmaceuticals SPA

 

By Mechanism of Action

By Distribution Channel

By Region

·         Dopamine Agonists

·         Anticholinergic

·         MAO-B Inhibitors

·         Amantadine

·         Carbidopa-levodopa

·         COMT Inhibitors

·         Other Mechanisms of Action

·         Retail Pharmacies

·         Hospital Pharmacies

·         Others

·         North America

·         Asia-Pacific

·         Europe

·         South America

·         Middle East & Africa

 

Report Scope:

In this report, the Global Parkinson’s Disease Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •  Parkinson’s Disease Drugs Market, By Mechanism of Action:

o   Dopamine Agonists

o   Anticholinergic

o   MAO-B Inhibitors

o   Amantadine

o   Carbidopa-levodopa

o   COMT Inhibitors

o   Other Mechanisms of Action

  • Parkinson’s Disease Drugs Market, By Distribution Channel:

o   Retail Pharmacies

o   Hospital Pharmacies

o   Others

  • Global Parkinson’s Disease Drugs Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Parkinson’s Disease Drugs Market.

Available Customizations:

Global Parkinson’s Disease Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Parkinson’s Disease Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Parkinson’s Disease Drugs Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and Other Mechanisms of Action)

5.2.2.    By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)

5.2.3.    By Region

5.2.4.    By Company (2022)

5.3.  Market Map

6.    Asia Pacific Parkinson’s Disease Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Mechanism of Action

6.2.2.    By Distribution Channel

6.2.3.    By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.    China Parkinson’s Disease Drugs Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Mechanism of Action

6.3.1.2.2.           By Distribution Channel

6.3.2.    India Parkinson’s Disease Drugs Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Mechanism of Action

6.3.2.2.2.           By Distribution Channel

6.3.3.    Australia Parkinson’s Disease Drugs Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Mechanism of Action

6.3.3.2.2.           By Distribution Channel

6.3.4.    Japan Parkinson’s Disease Drugs Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Mechanism of Action

6.3.4.2.2.           By Distribution Channel

6.3.5.    South Korea Parkinson’s Disease Drugs Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Mechanism of Action

6.3.5.2.2.           By Distribution Channel

7.    Europe Parkinson’s Disease Drugs Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Mechanism of Action

7.2.2.    By Distribution Channel

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Parkinson’s Disease Drugs Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Mechanism of Action

7.3.1.2.2.           By Distribution Channel

7.3.2.    Germany Parkinson’s Disease Drugs Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Mechanism of Action

7.3.2.2.2.           By Distribution Channel

7.3.3.    Spain Parkinson’s Disease Drugs Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Mechanism of Action

7.3.3.2.2.           By Distribution Channel

7.3.4.    Italy Parkinson’s Disease Drugs Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Mechanism of Action

7.3.4.2.2.           By Distribution Channel

7.3.5.    United Kingdom Parkinson’s Disease Drugs Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Mechanism of Action

7.3.5.2.2.           By Distribution Channel

8.    North America Parkinson’s Disease Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Mechanism of Action

8.2.2.    By Distribution Channel

8.2.3.    By Country

8.3.  North America: Country Analysis

8.3.1.    United States Parkinson’s Disease Drugs Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Mechanism of Action

8.3.1.2.2.           By Distribution Channel

8.3.2.    Mexico Parkinson’s Disease Drugs Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Mechanism of Action

8.3.2.2.2.           By Distribution Channel

8.3.3.    Canada Parkinson’s Disease Drugs Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Mechanism of Action

8.3.3.2.2.           By Distribution Channel

9.    South America Parkinson’s Disease Drugs Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Mechanism of Action

9.2.2.    By Distribution Channel

9.2.3.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Parkinson’s Disease Drugs Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Mechanism of Action

9.3.1.2.2.           By Distribution Channel

9.3.2.    Argentina Parkinson’s Disease Drugs Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Mechanism of Action

9.3.2.2.2.           By Distribution Channel

9.3.3.    Colombia Parkinson’s Disease Drugs Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Mechanism of Action

9.3.3.2.2.           By Distribution Channel

10. Middle East and Africa Parkinson’s Disease Drugs Market Outlook

10.1.             Market Size & Forecast

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Mechanism of Action

10.2.2. By Distribution Channel

10.2.3. By Country

10.3.             MEA: Country Analysis

10.3.1. South Africa Parkinson’s Disease Drugs Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Mechanism of Action

10.3.1.2.2.         By Distribution Channel

10.3.2. Saudi Arabia Parkinson’s Disease Drugs Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Mechanism of Action

10.3.2.2.2.         By Distribution Channel

10.3.3. UAE Parkinson’s Disease Drugs Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Mechanism of Action

10.3.3.2.2.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Parkinson’s Disease Drugs Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Amneal Pharmaceuticals LLC

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   AbbVie Inc.

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Boehringer Ingelheim International GmbH

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   GSK plc

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   Teva Pharmaceuticals Industries Ltd

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   Pfizer Inc.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Novartis AG

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   F. Hoffmann-La Roche Ltd

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   Kissei Pharmaceutical Co., Ltd.

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.AstraZeneca Plc

16.10.1.                  Business Overview

16.10.2.                  Company Snapshot

16.10.3.                  Products & Services

16.10.4.                  Financials (In case of listed companies)

16.10.5.                  Recent Developments

16.10.6.                  SWOT Analysis

16.11.Prevail Therapeutics Inc.

16.11.1.                  Business Overview

16.11.2.                  Company Snapshot

16.11.3.                  Products & Services

16.11.4.                  Financials (In case of listed companies)

16.11.5.                  Recent Developments

16.11.6.                  SWOT Analysis

16.12.Newron Pharmaceuticals SPA

16.12.1.                  Business Overview

16.12.2.                  Company Snapshot

16.12.3.                  Products & Services

16.12.4.                  Financials (In case of listed companies)

16.12.5.                  Recent Developments

16.12.6.                  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Parkinson’s Disease Drugs Market was estimated to be USD 4.80 billion in 2022.

down-arrow

Prevail Therapeutics Inc., Newron Pharmaceuticals SPA are some of the key players operating in the Global Parkinson’s Disease Drugs Market.

down-arrow

Balancing symptom relief with side effect management is an ongoing challenge for clinicians.

down-arrow

There is a growing trend on patient-centric approaches, including personalized medicine.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Parkinson’s Disease Drugs Market to grow with a CAGR of 7.50%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Parkinson’s Disease Drugs Market.

Why Choose Us